ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819

Its studies are mostly in Lupus Nephritis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Lymphoma, B-Cell, led by Fate Therapeutics.

Drug pageIPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Apr 30, 20263 company-led studies, 3 open or runningNext primary completion: Sep 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fate Therapeutics33 open or runningphase 2since Apr 30, 2026Nov 10, 2020Sep 30, 2027phase 1 · NCT06308978

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2020First study: phase 1 study in Lymphoma, B-CellFirst studyNCT04629729 · 54 enrolled · United States
  2. Mar 6, 2024Phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06308978 · 244 planned · United States, France, Sweden and more
  3. Apr 30, 2026Phase 2 study in Lupus NephritisPhase 2 reachedNCT07570862 · 53 planned · United States

Ahead

  1. Sep 30, 2027Primary completion: phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06308978
  2. Jul 1, 2029Primary completion: phase 2 study in Lupus NephritisNCT07570862

TargetBeta

CD19 →read by rule
“A preparation of off-the-shelf (OTS) T-lymphocytes, generated from an induced pluripotent stem cell (iPSC) line, that have been genetically modified to express a CD19 1XX chimeric antigen receptor (CAR) that targets the tumor-associated antigen (TAA) CD19, ”NCIt, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07570862Lupus Nephritis · United States2RecruitingJul 1, 202953
NCT06308978Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States, France, Sweden and more1RecruitingSep 30, 2027244
NCT04629729Lymphoma, B-Cell · United States1Active, not recruitingJun 18, 202554

How it is read

Names in the registry

  • “FT819”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.